62 research outputs found

    A Hybrid Evolutionary Multiobjective Approach for the Component Selection Problem

    No full text

    Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia

    No full text
    Recently, resveratrol showed induction of γ-globin mRNA synthesis in human erythroid precursors and reducing oxidative stress in red cells of thalassemia patients in many in vitro studies. We aimed to investigate the efficacy and safety of resveratrol, for the first time, in non-transfusion-dependent beta-thalassemia intermedia (B-TI) in Southern Iran. In this double-blind randomized clinical trial, 54 patients with B-TI were investigated during 6 months between October 2016 and March 2017. Patients were randomly allocated into three groups by simple randomization method. Group 1 (hydroxyurea (HU) and placebo, 18 patients), group 2 (resveratrol/piperine and placebo, 16 patients), and group 3(HU and resveratrol/piperine, 20 patients). Primary end point was considered as change in hemoglobin (Hb) levels and need for blood transfusion. Drug safety was considered as a secondary end point. Mean age of the patients was 28.2 ± 5.6 (18Ăąïżœïżœ42) years. Response rate was not significantly different among the three groups (P > 0.05). Higher percentages of adverse events were detected in groups 2 (31.3) and 3 (25) compared to group 1 (5.6). However, the difference was not statistically significant (P > 0.05). All reported adverse events were gastrointestinal symptoms. Resveratrol showed a similar efficacy with HU in the small population of non-transfusion B-TI patients during a 6-month follow-up. Complications, mostly gastrointestinal, were observed more frequently in resveratrol groups compared to the HU group. Although it was not statistically significant, more attention should be given to safety and efficacy of resveratrol as an oral HbF-augmenting agent. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature

    Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia

    No full text
    Recently, resveratrol showed induction of γ-globin mRNA synthesis in human erythroid precursors and reducing oxidative stress in red cells of thalassemia patients in many in vitro studies. We aimed to investigate the efficacy and safety of resveratrol, for the first time, in non-transfusion-dependent beta-thalassemia intermedia (B-TI) in Southern Iran. In this double-blind randomized clinical trial, 54 patients with B-TI were investigated during 6 months between October2016 and March 2017. Patients were randomly allocated into three groups by simple randomization method. Group 1 (hydroxyurea (HU) and placebo, 18 patients), group 2 (resveratrol/piperine and placebo, 16 patients), and group 3(HU and resveratrol/piperine, 20 patients). Primary end point was considered as change in hemoglobin (Hb) levels and need for blood transfusion. Drug safety was considered as a secondary end point. Mean age of the patients was 28.2 ± 5.6 (18Ăąïżœïżœ42) years. Response rate was not significantly different among the three groups (P > 0.05). Higher percentages of adverse events were detected in groups 2 (31.3) and 3 (25) compared to group 1 (5.6). However, the difference was not statistically significant (P > 0.05). All reported adverse events were gastrointestinal symptoms. Resveratrol showed a similar efficacy with HU in the small population of non-transfusion B-TI patients during a 6-month follow-up. Complications, mostly gastrointestinal, were observed more frequently in resveratrol groups compared to the HU group. Although it was not statistically significant, more attention should be given to safety and efficacy of resveratrol as an oral HbF-augmenting agent. © 2018 Springer-Verlag GmbH Germany, part of Springer Natur

    Bone Markers Status in Graves’ disease before and after Treatment

    No full text
    "nBackground:  Bone turnover is reported to increase in favor of resorption in overt hyperthyroidism and the rate of resorp­tion is associated with the levels of thyroid hormones. As persistent increase in bone turn over is responsible for accelerated bone loss, patients with Graves' disease may have increased risk for osteoporosis. The aim of this study was to determine relationship between Graves' disease and bone markers."nMethods: The subjects of our study were 31 consecutive untreated GD patients and 37 normal volunteers who were matched on sex proportion and age ranging was diagnosed by suppressed levels of TSH and elevated level of free T3 and free T4 and positive thyroid receptor antibody. Through a clinical trial study executed in endocrinology and metabolism research center, we investigated the relationship between serum osteocalcin & cross-laps with Graves' disease and then kinds of treatment with PTU and methimazole after 8 weeks follow up."nResults: No significant differences in age and sex between patients and controls were found. Significant differences in se­rum bone markers and thyroid hormones were detected between patients and controls before therapy (p< 0.001). After treatment we found a significant improvement and returning to normal range in all serum lab tests. There were not any dif­ferences in the effect of treatment on thyroid hormones and bone markers between two groups."nConclusion: We found close relationship between Graves' disease and bone markers. So that treatment of Graves' disease can improve bone turn over. These findings indicated that early diagnosis and management of Graves' disease can be effec­tive for osteoporosis prevention in these patients

    HYPOTHYROIDISM FOLLOWING THYROID SURGERY

    No full text
    Postsurgical hypothyroidism and its incidence has not been fully investigated. In this study, the incidence of hypothyroidism and its possible risk factors at Shariati Hospital was assessed. One hundred and two patients with benign thyroid diseases, who had undergone thyroidectomy, were investigated with regards to thyroid function profile during period of one year after the operation every three months with post-operative sample as the baseline. Hypothyroidism was developed in 36 patients (35.2%) on average 5 ± 3.2 months after surgery. Factors such as increased age, operation type, histopathologic type, underlying disease, lymphocytic infiltration and use of levothyroxine before surgery were associated with the increased incidence of hypothyroidism. It seems that use of indicators such as Graves' disease and lymphocytic infiltration in pathologic specimens should be helpful in projecting the potential occurrence of hypothyroidism in patients undergoing thyroidectomy
    • 

    corecore